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The extent to which variants in the protein-coding sequence of genes contribute to risk of rheumatoid arthritis (RA) is unknown.
In this study, we addressed this issue by deep exon sequencing and large-scale genotyping of 25 biological candidate genes located
within RA risk loci discovered by genome-wide association studies (GWASs). First, we assessed the contribution of rare coding
variants in the 25 genes to the risk of RA in a pooled sequencing study of 500 RA cases and 650 controls of European ancestry.
We observed an accumulation of rare nonsynonymous variants exclusive to RA cases in IL2RA and IL2RB (burden test: p ¼ 0.007
and p ¼ 0.018, respectively). Next, we assessed the aggregate contribution of low-frequency and common coding variants to the
risk of RA by dense genotyping of the 25 gene loci in 10,609 RA cases and 35,605 controls. We observed a strong enrichment of
coding variants with a nominal signal of association with RA (p < 0.05) after adjusting for the best signal of association at the loci
(penrichment ¼ 6.4 3 104). For one locus containing CD2, we found that a missense variant, rs699738 (c.798C>A [p.His266Gln]),
and a noncoding variant, rs624988, reside on distinct haplotypes and independently contribute to the risk of RA (p ¼ 4.6 3 106).
Overall, our results indicate that variants (distributed across the allele-frequency spectrum) within the protein-coding portion
of a subset of biological candidate genes identified by GWASs contribute to the risk of RA. Further, we have demonstrated that
very large sample sizes will be required for comprehensively identifying the independent alleles contributing to the missing
heritability of RA.Introduction
Genome-wide association studies (GWASs) have success-
fully identified many loci that influence a wide variety
of complex diseases. However, a large portion of the herita-
bility of complex traits has not been explained by GWASs.1
Several hypotheses have been proposed to explain the
missing heritability from association studies. One hypoth-
esis involves rare and low-frequency variants, which are
not well captured by current genotyping arrays. These
variants are expected to be under purifying selection and
thus enriched with deleterious, protein-coding mutations
participating in complex traits.2,3 Another hypothesis to
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Methods have been developed for the assessment of the
genetic architecture of complex traits with the use of
GWAS data.4,5 In a recent study,6 we used polygenic
models to demonstrate that common variants with weak
effect sizes account for a large portion of the missing
genetic contribution to diseases. Furthermore, we conduct-
ed Bayesian inference analyses and found that a portion of
the underlying risk is contributed by low-frequency and
rare causal variants and that these variants have modest
effect sizes (odds ratios [ORs] < 1.5). Our simulations sug-
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and independent low-frequency or rare causal variants
contribute to disease risk.
Investigating independent risk alleles affecting protein-
coding regions in associated loci appears to be a good
strategy for identifying genes of biological relevance in
complex traits. Indeed, several examples in the literature
show that genes containing common variants associated
with complex traits also contain rare and low-frequency
protein-coding variants; such genes include PCSK9 (MIM
607786; associated with low-density-lipoprotein choles-
terol levels),7 IFIH1 (MIM 606951; associated with type 1
diabetes),8 genes associated with hypertriglyceridemia9 or
inflammatory bowel disease,10,11 CFH (MIM 134370; asso-
ciated with age-related macular degeneration),12 MTNR1B
(MIM 600804; associated with type 2 diabetes),13 SHANK2
(MIM 603290; associated with autism spectrum disor-
ders),14 and CARD14 (MIM 607211; associated with
psoriasis).15
Here, we aimed to further assess the role of rare, low-
frequency, and common variants with weak effects on
the genetic architecture of rheumatoid arthritis (RA [MIM
180300]). We focused on variants within protein-coding
regions (e.g., missense, nonsense, and synonymous vari-
ants) because it is more straightforward to annotate biolog-
ical function and because independent protein-coding
variants can help pinpoint causative genes. Our findings
support our simulated genetic models and provide strong
evidence that rare, low-frequency, and common variants
within protein-coding sequences of biological candidate
genes from GWASs contribute to the risk of RA.Subjects and Methods
Samples
Our sequencing study included 500 RA cases and 650 matched
controls of European ancestry. RA cases were selected on the basis
of a high titer of anticitrullinated protein antibodies (ACPAs),
markers of disease severity.16 These samples originated from two
different collections. A total of 250 RA cases and 250 controls
were recruited from Sweden as part of the Epidemiological Inves-
tigation of Rheumatoid Arthritis.17 The remaining 250 cases and
400 controls were recruited from the United States as part of
a study using electronic medical records.18 Blood samples were
collected according to protocols approved by local institutional
review boards. All individuals provided informed consent.Exon Sequencing
We targeted 25 biological candidate genes in RA-associated loci by
using GRAIL19 for exon resequencing. We combined DNA in 10
pools of RA cases and 13 pools of matched controls, and each
pool contained the same amount of DNA from 50 individuals.
We matched case and control samples in pools for sequencing
by first calculating principal-component (PC) distances between
all pairs of samples as Euclidean distances along five eigenvalue-
weighted PCs (calculated from GWAS data). We matched one
control sample to each case by randomly choosing from nearby
controls (probability was inversely proportional to PC distance)
and minimizing the total case-control PC distance over 100 itera-16 The American Journal of Human Genetics 92, 15–27, January 10, 2tions, and we excluded outliers from the distribution of case-
control PC distances. We then established case pools by randomly
choosing pools from nearby cases and minimizing total within-
pool PC distance over 1,000 iterations, and matched controls
constituted matching control pools. For each pool, we performed
PCR amplification to capture the target sequence. We then
combined all PCR amplicons (~125 bp per amplicon) in equimolar
concentrations. Each pool was paired-end sequenced at the Broad
Institute on one lane of the Illumina Genome Analyzer II. Reads of
125 bp were aligned to the reference human genome (NCBI Build
36/hg18) with the MAQ algorithm20 within the Picard analysis
pipeline, similar to methods described in other studies.11
We used the method Syzygy to call variants on the pooled
sequencing data.11 We applied several filters to identify high-
quality variants in each pool. First, we considered only the posi-
tions with R2,0003 coverage, i.e., a minimum of 203 coverage
per chromosome. Second, we required concordant allele frequen-
cies on the forward and reverse strands. Third, we considered the
nonrandomness of the noise spectrum of technical artifacts due to
a biased preference for different base signal channels. Fourth, we
filtered out all SNPs that clustered together within a 5 bp window
centered on a SNP. Finally, because we sequenced the 23 pools in
three separate batches, we performed regression analyses to deter-
mine whether significant batch effects existed in our data. After
these stringent filtering criteria, 281 coding variants were called.
We used GWAS data available for 250 RA cases and 250 controls
to assess the quality of the variants called. First, we targeted
18 low-frequency variants that were genotyped with GWAS
arrays and determined whether we were able to detect singletons,
doubletons, tripletons, and all alleles present at a frequencyR 4 in
each pool sequenced. We detected 99% of all singletons and 100%
of all doubletons and tripletons in our sequencing data. Our
approach missed one singleton as a result of low coverage at that
base (nreads ¼ 184). To determine the specificity in our data, we
took advantage of a larger set of SNPs present in both our
sequencing data and our GWAS data (n ¼ 40, genotyped or
imputed). The allele frequencies estimated from read counts corre-
lated strongly with expected frequencies in the GWAS pools
(pearson correlation, R2cases ¼ 0.990 and R2controls ¼ 0.999).
We achieved slightly diminished specificity (R2cases ¼ 0.934
and R2controls ¼ 0.972) with lower-frequency variants
(frequencysyzygy < 0.05, n ¼ 25; Table S2 and Figure S1, available
online). We used PolyPhen21 to annotate the 281 variants
(missense, nonsense, or synonymous) and predict their impact
on the structure and function of the protein.Analysis of Burden Association Signal Due to Rare
Variants
To assess the overall genetic burden due to rare variants in the
genes investigated, we used four collapsing methods described in
the literature: (1) the weighted-sum statistic described by Madsen
and Browning,22 (2) the variable-threshold model described by
Price et al.,23 (3) the T1 and T5 models by Morris and Zeggini,24
and (4) the C-alpha test described by Neale et al.25 In this analysis,
we only included variants that were not previously described in
the 1000 Genomes CEU (Utah residents with ancestry from
northern and western Europe from the CEPH collection) panel
(release June 2011) or in dbSNP. For each gene, we separated the
nonsynonymous and synonymous variants. We then pooled the
variants on the basis of their minor allele frequency (MAF) in
controls (MAF < 1% or MAF < 5%) and tested their cumulative013
effect by using the four collapsing methods and allele counts in
the pooled data (note: singletons were not included in the C-alpha
test). We repeated the analysis by incorporating PolyPhen predic-
tions in the statistical tests and giving higher weight to variants
predicted to be functionally relevant. We assessed statistical signif-
icance by 100,000 case-control permutations.
Single SNP Analysis Using Genotype Data
To test the low-frequency and common coding variants for associ-
ation with RA, we used two types of genotyping data available in
our laboratory (Table S3). Seven case-control collections were gen-
otyped with the Illumina Immunochip platform as part of the
Rheumatoid Arthritis Consortium International,26 the i2b2
program,18 or the Consortium of Rheumatology Researchers of
North America (CORRONA).27 Four additional case-control collec-
tions from our previous GWAS were included.28
The i2b2 samples were identified with the use of clinical data
from the electronic medical records (EMRs) as previously
described.29 The i2b2 and CORRONA samples were genotyped
together at the Broad Institute. Genotype calling was performed
on all samples as a single project with the GenomeStudio Data
Analysis Software package. Initial genotype clustering was per-
formed with the default Illumina cluster file (Immunochip_
Gentrain_June2010.egt) and manifest file Immuno_BeadChip_
11419691_B.csv. Extensive quality control and data filtering
were performed as described elsewhere,26 and SNPs with p <
102 in a chi-square test for difference in missingness between
cases and controls were also removed, leaving 148,972 SNPs
for subsequent analysis. We performed PC analysis by using
EIGENSOFT30 with HapMap phase III samples to exclude individ-
uals of non-European ancestry.
We calculated identity-by-state estimates by using PLINK31 to
remove related samples across the Immunochip and GWAS
collections with the use of a set of SNPs with a missing-genotype
rate < 0.5%, MAF > 5%, and pruned linkage disequilibrium
(LD). The 11 collections resulted in a total sample size of 10,609
RA ACPAþ cases and 35,605 controls of European ancestry. We
applied stringent filters on each Immunochip data set to select
only high-quality SNPs for association testing (call rate > 0.99 in
cases and controls, MAF > 0.1%, Hardy-Weinberg equilibrium
p< 53 107, and p> 102 in chi-square test for difference inmiss-
ingness between cases and controls). GWAS collections were
imputed with the use of SNPs from the 1000 Genomes CEU
reference panel (release June 2011), and SNPs with bad statistical
information (info score < 0.4) or a MAF < 0.1% were removed
in the subsequent analysis.
To test for association with RA risk, we used PLINK to conduct
logistic-regression analyses of the 11 RA case-control collec-
tions, and this included ten PCs calculated as covariates with
EIGENSOFT.30 After checking genomic-control inflation in each
collection, we conducted an inverse-variance-weighted meta-
analysis to combine the results across the 11 collections at each
of the loci of interest. We also computed Cochran’s Q statistics
and I2 statistics to assess heterogeneity across collections. Meta-
analysis and computation of heterogeneity statistics were adapted
from the MANTEL program.32 At each of the loci analyzed, we
performed a conditional analysis in PLINK to test for an indepen-
dent signal of association by adjusting for the genotypes at the
best signal of association at the locus. When the SNP with the
best signal of association was not present in the 11 collections,
the best proxy (r2 > 0.9) present in the 11 collections was used
in the conditional analysis. We also performed a conditional anal-The Amysis by adjusting for the coding variants to assess the contribution
of these coding variants to the known GWAS signals.
To assess the enrichment of coding variants with nominal signal
of association in our meta-analysis and conditional analysis (pob-
served < 0.05), we generated 1,000 sets of permuted phenotypes
for each of the 11 collections. For each collection, we performed
1,000 logistic regressions (including ten PCs as covariates) by
using the permuted phenotypes. We then performed 1,000
meta-analyses of the logistic-regression results from the 11
collections. We extracted the p values (ppermutation) for each of
the SNPs with pobserved< 0.05 in our initial meta-analysis or condi-
tional analysis. For several p value thresholds (pthreshold ranging
from 5 3 108 to 1), we compared the number of SNPs with
pobserved < pthreshold and ppermutation < pthreshold and assessed the
significance of the results by using Fisher’s exact tests.
To assess the significance of observing coding SNPs in LD
(r2 > 0.7) with the best signals of association at the loci, we
randomly extracted 1,000 SNPs from each of the loci of interest.
We then compared the frequency of randomly extracted SNPs
that showed r2 > 0.7 with the best hit in the conditional analysis
to the observed frequency among coding SNPs with p < 0.05 in
the conditional analysis (Fisher’s exact test).Independent Signal of Association at CD2
To investigate the independent signal of association at CD2, we
performed a conditional haplotype analysis in PLINK by using
only samples genotyped in the Immunochip (7,222 RA cases
and 15,870 controls) and including PCs as covariates. To assess
the significance of the results controlling for the known common
variant, we permuted case-control status while preserving geno-
types for the common variant (fixing case-control allele frequen-
cies and ORs). In 5,000 permutations, we evaluated the frequency
of observing a signal of association at p% 0.015 when controlling
for the common variant.
To investigate the best causal candidate variant responsible for
this independent signal, we extracted all SNPs that were described
in the 1000 Genomes CEU data (release June 2011) and that were
in strong LD (r2 > 0.8) with rs798036. We annotated the 17
proxies by using PolyPhen,21 SIFT,33 GERP,34 and publically avail-
able data on expression quantitative trait loci (eQTL).Power Calculations
To assess the number of samples required for reaching significant p
values in our burden tests, we extrapolated our results in IL2RA
and IL2RB, as described previously.35 We used (1) ORs estimated
on the basis of singleton counts in our 500 RA cases and in Euro-
pean American samples as part of the National Heart, Lung, and
Blood Institute (NHLBI) Exome Sequencing Project (ESP) and (2)
ORs estimated on the basis of allele counts for variants with a
MAF < 5% in our RA cases and controls. We calculated burden
p values by using a one-sided Fisher’s exact test.
Power to observe a p < 5 3 108 for association at the CD2
common missense variant was assessed with the Genetic Power
Calculator.36Results
Study Overview
An overview of our study is shown in Figure 1. We
sequenced the coding exons of 25 genes located withinerican Journal of Human Genetics 92, 15–27, January 10, 2013 17
Figure 1. Description of the Study Design
Our study used two sources of data: (1) we sequenced the coding exons of 25 genes located within RA risk loci identified by GWASs,
leading to the identification of 281 protein-coding variants (top panel: distribution shown for MAF in controls); and (2) we used inte-
grated Immunochip and GWAS data for 10,609 seropositive RA cases and 35,605 controls and focused only on the protein-coding vari-
ants from these same 25 genes. We performed three types of analyses: (1) To test for association, we investigated burden association
signals driven by an accumulation of rare variants (frequency < 0.5%). (2) We assessed the role of low-frequency (0.5%–5%) and
common (frequency> 5%) variants with weak effect in RA by adjusting for the common SNP identified by GWASs. (3) For detailed anal-
ysis, we selected the CD2 locus, which showed suggestive evidence of an independent signal of association in the conditional analysis.RA risk loci identified by GWASs. We focused our analysis
on the best biological candidate genes at each locus
because most RA-associated loci have evidenced connec-
tivity that implicates specific biological pathways.19,37
We investigated the implication of variants previously
not associated with risk of RA in two ways. First, we
investigated burden association signals driven by an accu-
mulation of rare variants (frequency < 0.5%). Second, we
assessed the role of independent low-frequency (0.5%–
5%) and common (frequency > 5%) variants with a weak
effect in RA by adjusting for the known common signals
of association identified by GWASs. To perform this anal-
ysis, we took advantage of a large genotyping data set
including Immunochip and GWAS data. Finally, for
detailed analysis, we selected theCD2 locus, which showed18 The American Journal of Human Genetics 92, 15–27, January 10, 2suggestive evidence of an independent signal of associa-
tion in the conditional analysis.
Identification of Coding Variants in Biological
Candidate Genes
We selected 25 biological candidate genes from loci associ-
ated with RA in previous GWASs28,38 by using GRAIL19 and
targeted them for exon sequencing in 500 RA cases sero-
positive for ACPAs and 650 matched controls of European
ancestry. Overall, 86.4% (ranging between 62.6% in
FCGR2A (MIM 146790) and 100% in CCL21 [MIM
602737] and CTLA4 [MIM 123890]) of the 36.8 kb target
regions were sequenced with >203 coverage per chromo-
some in at least 80% of case pools and control pools
(Table 1). The average coverage per position sequenced013
Table 1. Number of Coding Variants Identified in the Biological Candidate Genes through Exon Sequencing
Gene
Coding-Sequence
Length (bp)
Percentage
Covereda
Number of Variants
Total
Nonsynonymous Synonymous
All Testedb All Testedb
BLK 1,515 78.3% 17 11 8 6 3
CCL21 372 100.0% 2 1 1 1 0
CCR6 1,122 97.9% 9 3 1 6 3
CD2 1,053 92.9% 9 8 5 1 1
CD28 660 77.3% 4 2 2 2 0
CD40 831 84.7% 4 2 1 2 1
CD58 750 80.3% 6 4 3 2 1
CTLA4 669 100.0% 2 2 1 0 0
FCGR2A 951 62.6% 7 3 2 4 2
IL2 459 86.9% 1 0 0 1 0
IL21 486 78.4% 2 0 0 2 1
IL2RA 816 92.2% 11 7 4 4 2
IL2RB 1,653 91.9% 13 9 6 4 3
IRF5 1,494 85.5% 7 4 4 3 1
PRDM1 2,475 85.9% 21 13 6 8 5
PRKCQ 2,118 97.5% 23 11 8 12 8
PTPN22 2,421 86.8% 19 14 9 5 4
PTPRC 3,912 84.6% 37 21 16 16 10
REL 1,857 77.2% 5 2 2 3 2
STAT4 2,244 91.0% 8 4 2 4 3
TAGAP 2,193 78.6% 16 10 7 6 4
TNFAIP3 2,370 97.2% 14 10 8 4 2
TNFRSF14 849 80.4% 11 6 3 5 2
TRAF1 1,248 86.1% 19 10 7 9 6
TRAF6 1,566 81.9% 14 10 10 4 4
Total 36,084 86.4% 281 167 116 114 68
aPercentage of coding sites sequenced with >203 coverage per chromosome in at least 80% of case pools and control pools.
bVariants absent from dbSNP and the 1000 Genomes Project (release June 2011) and included in the collapsing tests and burden tests.and per pool was 90,7003, i.e., 9073 coverage per position
per chromosome.
We used the calling variant method Syzygy11 and identi-
fied 281 high-quality coding variants, i.e., one variant
every 128 bp (Table 1 and Table S1). Using GWAS data
available for 250 case-control pairs included in our
sequencing study, we found high sensitivity and specificity
of our sequencing results (Table S2 and Figure S1). The
transition-to-transversion ratio based on the 281 SNPs
was 3.6, consistent with previously published ratios from
exon-sequencing data.3
Out of the 281 variants, 232 (83%) had a MAF less than
1% in controls, and as expected, only 97 (35%) were previ-
ously described in the 1000 Genomes Project or dbSNP,
showing that most of the variants identified here areThe Amboth rare and previously uncharacterized. The 281 variants
included 114 synonymous, 164 missense, and 3 nonsense
variants. We used PolyPhen21 to predict the function of
the missense variants. A total of 32 (20%) and 43 (26%)
variants were predicted to be potentially damaging
and probably damaging, respectively (Table S1). Among
the synonymous variants, 26 (23%) had a conservation
score > 2 as determined by GERP,34 giving some evidence
of evolutionary constrained sites (Table S1).
Accumulation of Nonsynonymous Rare Variants in
IL2RA and IL2RB in Individuals with RA
To assess association at rare variants, we used four
collapsing (or burden) methods described in the literature.
The weighted-sum statistic,22 the variable-thresholderican Journal of Human Genetics 92, 15–27, January 10, 2013 19
Figure 2. Accumulation of Coding Rare Variants in IL2RA and IL2RB
(A) Burden association signal driven by nonsynonymous variants. Two types of tests were performed: unweighted (UW) tests and tests
weighted (W) with PolyPhen scores. For these two genes, we did not obtain any result by using the C-alpha method because it did not
include singletons.
(B) Accumulation of rare variants exclusive to RA cases in IL2RA and IL2RB.
(C and D) Distribution of variants across IL2RA and IL2RB. Missense, nonsense, and synonymous variants are shown in red, brown, and
green, respectively. For the missense variants, PolyPhen prediction is indicated (B, benign; d, potentially damaging; and D, probably
damaging). Variants included in the collapsing tests and burden tests (i.e., variants not described in the 1000 Genomes Project or in
dbSNP) are highlighted with a star.model,23 and the T1 and T5 models24 assume that the
effects of the combined variants on the phenotype are in
the same direction, whereas the C-alpha test25 allows
detection of opposite effects. For our primary analysis, we
restricted the burden tests to variants not described in
dbSNP or the 1000 Genomes Project (release June 2011)
under the hypothesis that truly private mutations are
more likely to be pathogenic. We tested groups of nonsy-
nonymous (n ¼ 116) and synonymous (n ¼ 68) variants
separately; for the nonsynonymous variants, we per-
formed both unweighted tests and tests incorporating
PolyPhen predictions of the functional effect of the vari-
ants in the statistical tests such that higher weight was
attributed to variants predicted to have functional impact.
In a second analysis, we performed gene burden tests by
using all nonsynonymous variants identified, weighted,
and unweighted with PolyPhen prediction scores.
Two genes, IL2RA (MIM 147730) and IL2RB (MIM
146710), showed nominal burden signal of association (p
< 0.05) driven by two or more nonsynonymous variants
(Figure 2A). In IL2RA and IL2RB, four and six nonsynony-
mous variants, respectively, were included in the tests. In
IL2RA, incorporating PolyPhen prediction did not affect
the burden signal observed, whereas IL2RB variants pre-
dicted to be potentially or probably damaging did influ-20 The American Journal of Human Genetics 92, 15–27, January 10, 2ence the genetic-burden signal (Figure 2A). The same
results were observed when we included all nonsynony-
mous variants in the tests; the only exception was
PTPN22 (MIM 600716), which only reached p < 0.05
when we included the known RA-risk missense variant
rs2476601 (data not shown).
The burden signal at IL2RA and IL2RB corresponded to
an accumulation of nonsynonymous rare variants, mainly
singletons, exclusively identified in cases (Figures 2B–2D).
The burden signal of association at these two genes could
not be attributed to a bias in the sequencing coverage
between case and control pools given that all ten variants
included in the IL2R burden tests showed >50,0003
coverage in each pool (i.e > 5003 coverage per chromo-
some per pool). The distribution of the variants across
the genes highlighted that eight out of the nine cases-
exclusive nonsynonymous variants in IL2RA and IL2RB
lie within the extracellular-domain-coding regions (Figures
2C and 2D).
We further assessed the frequency of singleton missense
SNPs in IL2RA and IL2RB among 4,300 individuals of Euro-
pean ancestry from the NHLBI ESP. None of the singleton
variants in IL2RA and IL2RB were present in the ESP data
(four IL2RA and four IL2RB singleton variants in RA
cases). Among ESP samples, only six missense singletons013
(12 missense SNPs with a MAF < 5%) were identified
in IL2RA and 12 missense singletons (22 missense
SNPs with a MAF < 5%) were identified in IL2RB. Using
our sequencing results from RA samples (n ¼ 500 RA
cases) and the ESP data as controls (n ¼ 4,300 controls)
in one-sided Fisher’s exact tests incorporating single-
tons, we observed the following ORs: IL2RA, OR ¼ 5.75
(p ¼ 0.02); and IL2RB, OR ¼ 2.9 (p ¼ 0.08). These
results are consistent with the observed effect sizes from
our sequencing results in IL2RB (OR ¼ 3.0), providing
supporting evidence that missense mutations in these
two genes contribute to risk of RA. (We could not deter-
mine the OR in IL2RA on the basis of our sequencing
results because no rare missense variant was identified in
our controls).
Enrichment of Signals of Association at Coding
Variants
The genetic-burden tests described above do not test the
role of single variants whether the variants are of low
frequency (0.1%–5%) or common (>5%) in the general
population. To extend our sequencing study to indepen-
dent modest-effect variants that are sufficiently frequent
to be cataloged and genotyped with current arrays, we
took advantage of two large RA case-control genotyping
data sets: (1) 8,246 RA cases and 17,741 controls of Euro-
pean ancestry from seven collections and genotyped at
high density across autoimmune-disease-related loci with
the Illumina Immunochip (iChip) platform26 (and unpub-
lished data) and (2) a GWAS data set including 2,363 RA
cases and 17,872 controls of European ancestry from four
collections28 (Table S3). The iChip data described here
include a new set of 1,024 RA cases and 1,863 controls
not previously analyzed. Also, our GWAS data set reported
here was imputed genome-wide with haplotype-phased
1000 Genomes CEU data as a reference panel for the
improvement of coverage of low-frequency variants.
We first assessed the coverage of variants discovered by
sequencing in the iChip and GWAS data sets. By exam-
ining good proxies of the sequencing variants (r2 > 0.8,
as determined with the 1000 Genomes CEU data), we
found that 42 out of 60 SNPs observed with a MAF >
0.5% in controls in our sequencing study were tagged in
our quality-filtered genotyping data set. In contrast, 5 out
of 211 SNPs with a MAF < 0.5% in controls were tagged
in the genotyping data set (Figure 1). We focused on this
set of 47 SNPs for association testing in our combined
sample set of 10,609 RA ACPAþ cases and 35,605 controls.
Of the 47 coding variants, 23 were nonsynonymous vari-
ants and 24 were synonymous variants.
To test these 47 coding variants for association with RA
risk, we performed a meta-analysis of all data combined
and compared the association p values with meta-analysis
results after 1,000 case-controls permutations of the 11
data sets. After excluding variants in LD with each other
(r2 > 0.4), we observed 16 (37%) of the 43 independent
variants with p < 0.05 for association with RA, whereasThe Amthree were expected by chance alone (penrichment ¼ 1.4 3
108) (Table S4). The signal appeared to be driven by
both nonsynonymous variants (9/22 variants with p <
0.05; penrichment ¼ 8.5 3 104) and synonymous variants
(7/21 variants with p < 0.05; penrichment ¼ 5.9 3 104).
Conditional Analysis on Established, Common RA
Risk Alleles
To assess whether the signal observed at coding variants
was driven by the established common RA risk allele, we
first evaluated the LD between the 16 associated
coding variants and the known GWAS signals (Table S4).
Three of the 16 coding variants were in strong LD with
the known GWAS SNPs (r2 > 0.8), including the
well-known causal missense variant rs2476601 in
PTPN22.39–42 An additional four coding variants were in
moderate LD with the known GWAS SNP (2/16 variants
with r2 ¼ 0.4–0.8 and 2/16 variants with r2 ¼ 0.1–0.4),
and the other nine coding variants had an r2 < 0.05 with
the GWAS SNP.
To account for the known GWAS signal, we performed
conditional analyses adjusting for the best hit identified
in the meta-analysis at each locus. After conditional anal-
ysis, we identified 10 of 43 (23%) coding variants showing
p < 0.05 for association with RA risk; this was more than
expected by chance alone (penrichment ¼ 6.4 3 104). This
signal was driven by both nonsynonymous (6/22 variants;
penrichment ¼ 8.7 3 103) and synonymous variants (4/21
variants; penrichment ¼ 0.025) (Figure 3 and Table 2). One
of the coding variants with p < 0.05 is TNFAIP3 (MIM
191163), and a proxy of this nonsynonymous variant (r2
¼ 0.62) has been previously implicated as an RA risk
allele.43 After removing this coding TNFAIP3 variant, we
still observed evidence of enrichment (penrichment ¼ 2 3
103; Figure S2).
Although these observations strongly suggest that some
of the coding variants analyzed here are true risk alleles for
RA independent of the known RA risk alleles, no single
variant survived a stringent correction for multiple
hypotheses testing given the number of SNPs tested across
each locus. However, we did observe that five out of the ten
coding variants with pcondition < 0.05 were in LD (r
2 > 0.7)
with the best hit in the conditional analysis (penrichment ¼
1.73 103); the five remaining variants had r2 < 0.05 with
the best hit (Table 2). That is, if the coding variants had no
effect on risk of RA (i.e., spurious association), it is unlikely
that the coding variants would be in high LD with the
second strongest signal of association after conditioning
on the known GWAS signal.
We also performed a conditional analysis adjusting for
the coding variants and compared the association signal
at the known GWAS hit in the meta-analysis and the
conditional analysis (Table S5). As indicated by the consis-
tent ORs in both analyses, the ten coding variants showing
p < 0.05 when we adjusted for the known GWAS risk
alleles did not contribute to the known GWAS signals of
association.erican Journal of Human Genetics 92, 15–27, January 10, 2013 21
Figure 3. Enrichment of Nominal Association Signal Driven byNonsynonymous and Synonymous Variants in the Conditional Analysis
The numbers of nonsynonymous variants (A) and synonymous variants (B) reaching the p < p threshold in our conditional analysis
or after 1,000 permutations of the phenotypes are shown. Significant enrichment of SNPs with the p < p threshold in our conditional
analysis was assessed by a Fisher’s exact test (*p < 0.05 and **p < 0.01).Together, these data argue for a model in which at least
some RA risk loci harbor additional yet-unidentified low-
frequency or common risk alleles with a modest effect
size (OR z 1.2; Table 2). Importantly, these yet-undiscov-
ered independent association signals are most likely driven
by variants within the protein-coding sequence of genes.
Our results suggest that not only nonsynonymous but
also synonymous variants play a role in these independent
signals of association.
Independent Signal of Association at CD2
Most of the ten candidate coding variants identified above
showed either a small effect size or a low frequency, which
did not allow us to perform detailed follow-up analyses
with enough power considering the sample size of our
genotyping data set. However, one common missense
variant in CD2 (MIM 186990), rs699738 (c.798C>A
[p.His266Gln]), showed a pcondition ¼ 0.0017 and was in
complete LD (r2 ¼ 1) with the best signal of association
in the conditional analysis (MAF ¼ 0.09 and ORcondition ¼
0.88). We thus performed more detailed haplotype and
conditional analyses at the CD2 locus. Our meta-analysis
and conditional analysis provided suggestive statistical
evidence of association at both a common noncoding
variant (rs624988 [MAF ¼ 0.4]) and the independent
missense variant rs699738 (Table 2 and Figures 4A and
4B). Although rs699738 was not directly analyzed in our
meta-analysis, we identified proxy SNPs that were in
complete LD (r2 ¼ 1) and that were included in our meta-
analysis (these were rs798036, rs798037, rs798044, and
rs810048). As shown in Figure 4C, these proxy SNPs
showed consistent effect sizes among the 11 data sets and
thus association with RA risk in the meta-analysis. After
adjusting for both rs624988 and rs798036 in a conditional
analysis, we observed no signal at p < 0.01 (Figure S3).
In a haplotype analysis using iChip data (Figure 4D), we
observed that the perfect proxy of the missense variant22 The American Journal of Human Genetics 92, 15–27, January 10, 2(rs798036) was independent of the common variant
driving the best signal of association at the locus
(rs624988). For the three common haplotypes formed by
these two CD2 variants, there was a dose-dependent effect
on risk of RA on the basis of point estimates: the A-T haplo-
type with both risk alleles had a higher susceptibility
(OR¼ 1.22) than did the G-A haplotype with both nonrisk
alleles, whereas the G-T haplotype carrying the CD2
missense variant alone demonstrated an intermediate
effect (OR ¼ 1.14). (The A-A haplotype carrying the non-
coding risk variant alone was infrequent [1.6%] in the
general population and had anOR of 1.45 and a 95% confi-
dence interval of 1.13–1.85). Consistent with Figure 4B, we
observed a significant association for the G-A haplotype
carrying the CD2missense variant risk allele when control-
ling for the noncoding variant rs624988 (p ¼ 0.015). We
further assessed the significance of this result by perform-
ing 5,000 case-control permutations while preserving
genotypes for the common variant (fixing case-control
allele frequencies and ORs) and found that the observation
of a signal of association at p% 0.015 after controlling for
the effect of rs624988 is beyond what might be expected
by chance alone (p ¼ 0.014). Considering both variants
and all haplotypes combined, we observed a highly signif-
icant (p ¼ 4.6 3 106) association between the CD2 locus
and risk of RA.
Although the CD2 missense variant represents a strong
candidate for one of the causal alleles at the CD2 locus,
we considered the possibility that a noncoding variant
could also be responsible for the independent signal at
CD2. We identified 16 SNPs in strong LD (r2 > 0.8) with
missense variant rs699738. These SNPs included nine
intronic variants and seven variants in the 30 region of
the coding sequence. We used several publically available
tools and data sets to annotate the missense variant
(rs699738) and the 16 noncoding variants (Table S6): (1)
PolyPhen21 and SIFT33 to predict the function of the013
Table 2. Coding Variants Showing Nominal Signal of Association in the Conditional Analysis
Gene
Coding Variant Best Hitcondition
a
Reference
SNP ID MAF ORmeta (95% CI) pmeta pcondition
Reference
SNP ID pcondition r
2b
Missense Variants
TNFAIP3 rs2230926 0.038 1.38 (1.30–1.46) 6.8 3 1014 1.4 3 109 rs58721818 3.3 3 1010 0.87
FCGR2A rs1801274 0.494 1.10 (1.08–1.12) 2.4 3 107 5 3 104 index 5 3 104 1
CD2 rs699738c 0.086 0.88 (0.82–0.94) 1.2 3 104 0.0017 index 0.0017 1
TNFRSF14 rs2234163c 0.006 1.52 (1.28–1.76) 7.6 3 104 0.0019 rs1886731 8 3 104 ~0
BLK rs55758736 0.012 0.79 (0.61–0.97) 0.01 0.0077 rs77072957 1 3 104 ~0
TAGAP rs41267765 0.029 1.18 (1.08–1.20) 0.0018 0.0107 rs112904761 0.0017 0.76
Synonymous Variants
IL2RA rs2228150 0.03 1.25 (1.15–1.35) 6.6 3 106 6 3 104 rs11256360 5 3 104 0.88
IL2RB rs228953 0.44 0.95 (0.93–0.97) 0.0023 0.0042 rs5756391 4 3 104 ~0
CD58 rs35768283 0.02 1.20 (1.08–1.32) 0.0043 0.0117 rs798036 0.0017 ~0
TRAF1 rs3747841c 0.013 0.89 (0.72–1.07) 0.17 0.03 rs76418192 0.0037 ~0
The following abbreviations are used: MAF, minor allele frequency; OR, odds ratio; and CI, confidence interval.
aBest signal of association in the conditional analysis.
bLD between the coding variant and the best signal of association. Boldface indicates r2 > 0.7.
cCoding variants represented by a proxy in complete LD in the meta-analysis.missense variant, (2) GERP34 to identify evolutionary con-
strained sites, and (3) eQTL data in human CD4þ T cells
and monocytes.44,45 Missense variant rs699738 induces
the substitution of a histidine for a glutamine at position
266 of CD2 (p.His266Gln) but was predicted to be benign
by both PolyPhen and SIFT. None of the 17 noncoding
variants showed a high conservation score in mammals,
and we found no evidence that these SNPs are associated
with CD2 expression as eQTLs. All together, we found no
evidence to support a noncoding variant as being poten-
tially damaging.
Discussion
The extent to which variants across the allele-frequency
spectrum contribute to complex traits such as risk of RA
and the actual contribution of variants within protein-
coding sequences are two important issues in human
genetics. In this study, we addressed these two questions
by deep exon-sequencing and large-scale genotyping
across 25 genes from RA risk loci discovered by GWASs.
Our findings support a model in which most GWAS find-
ings in RA are due to common variants that fall outside
of the protein-coding sequences of genes. More impor-
tantly, however, we provide evidence of independent asso-
ciation signals driven by coding variants within a subset of
biological candidate genes identified by GWASs and show
that rare, low-frequency, and common variants with
a small to moderate effect size participate in the missing
genetic contribution to RA.
There are several important implications of our study.
First, we assessed the contribution of coding variants toThe Amrisk of RA. Although most of the candidate genes that we
sequenced did not have evidence of rare protein-coding
mutations contributing to risk of RA, we did find that, in
RA cases, two genes (IL2RA and IL2RB) harbor an accumu-
lation of rare missense variants that result in a moderate
burden signal of association (p ¼ 0.007 and p ¼ 0.018,
respectively; Figure 2). Further, by testing the aggregate
signal of association at variants that have a MAF > 0.1%
and that lie within protein-coding sequences from a subset
of biological candidate genes, we have demonstrated
a significant enrichment of coding variants with p < 0.05
(penrichment ¼ 6.4 3 104; Table 2 and Figure 3) and have
shown that these associated coding variants are observed
in LD (r2 > 0.7) with the second best hit at the loci more
frequently than would be expected by chance alone
(penrichment ¼ 1.7 3 103). Although this analysis cannot
definitively confirm which coding variants are causative,
our study does suggest that many will ultimately contri-
bute to risk of RA. To illustrate these findings, we provide
further evidence that one of these associated coding vari-
ants, altering the sequence of CD2, is independent of the
common noncoding variant driving the best signal of asso-
ciation at the locus, and we have shown that these two
variants form three common haplotypes conferring risk
of RA in a dose-dependent manner (Figure 4).
A second implication involves protein-codingmutations
to help identify the disease-causative genes at GWAS loci,
which in turn provides insight into disease biology.
As discussed above, this study identified three genes
carrying missense variants associated with risk of RA:
IL2RA, IL2RB, and CD2. IL2RA encodes IL-2Ra (CD25),
and IL2RB encodes IL-2Rb (CD122); all together, CD25,erican Journal of Human Genetics 92, 15–27, January 10, 2013 23
Figure 4. Evidence of an Independent Signal of Association at the CD2 Locus
(A and B) Association results from the meta-analysis (A) and the conditional analysis (B). In these analyses, missense SNP rs699738 is
represented by a group of SNPs, including rs798036 (highlighted in blue), in perfect LD (r2 ¼ 1). In each analysis, the best signal of
association is indicated by a diamond. Only SNPs present in more than five collections are shown.
(C) ORs and 95% confidence interval in the independent cohorts and the meta-analysis.
(D) Results from the haplotype analysis using the best signal in the meta-analysis (rs624988) and rs798036. In this analysis, only geno-
type data were used (7,222 RA cases and 15,870 controls). With this subset of samples, rs624988 and rs798036 reached p ¼ 1.3 3 105
and p ¼ 2 3 103 in the meta-analysis, respectively. The overall CD2 variation due to rs624988 and rs798036 contributed to RA with
p ¼ 4 3 106. The RA risk allele is highlighted in red.CD122, and the common gamma chain, CD132, consti-
tute the three subunits of the high-affinity IL-2 receptor
(IL2R).46 Studies have reported that the inactivation of
either CD25 or CD122 in mice results in lethal autoimmu-
nity.47,48 Furthermore, a risk allele in IL2RA has been
linked with a decreased function of T regulatory (Treg) cells
in type 1 diabetes.49,50 CD2 encodes a cell-surface antigen
expressed on T cells. CD2 coactivation has been shown to
induce the suppression of T cell proliferation by activation
of CD4þ CD25hi Treg cells.51,52 Interestingly, several
reports have shown that Treg cells, which control proin-
flammatory responses, are functionally compromised in
individuals with RA.53–55 Further validation and func-
tional analyses will be needed for supporting this observa-
tion and for assessing whether the protein-coding variants24 The American Journal of Human Genetics 92, 15–27, January 10, 2within these three genes affect the IL-2-signaling pathway,
the differentiation or activity of Treg cells, or other disease-
related processes to be determined.
A third implication addresses the allele-frequency spec-
trum and effect size of the variants participating in the
risk of RA. We have previously used simulations to show
that rare, low-frequency, and common variants of small
to modest effects participate in the missing genetic
contribution to RA.6 Here, we provide data to empirically
support this model. First, the moderate burden signals of
association at IL2RA and IL2RB implicate rare variants as
participating in the risk of disease. Second, the significant
enrichment of independent coding variants associated
with RA highlights low-frequency and common variants
with a modest effect size (OR z 1.2; Table 2) and shows013
that these signals of association are independent of the
known RA risk signals identified by GWASs (Table 2 and
Table S5). Importantly, these conclusions are based on
a small subset of candidate genes selected for sequencing.
A more comprehensive approach to genome sequencing
in RA will be required for assessing whether these findings
can be extrapolated to the remainder of the genome. Ulti-
mately, sequence data on the entire genome in large
sample collections will be required for understanding the
complete genetic architecture of RA risk.
A fourth implication pertains to the design and interpre-
tation of future large-scale sequencing and genotyping
studies in RA, as well as potentially other complex traits.
Our results strongly suggest that genes implicated by
GWASs serve as excellent candidates for future sequencing
studies. For example, itmight be informative to use compu-
tational methods such as GRAIL to prioritize genes for
sequencingor even the interpretationof results that emerge
from whole-genome-sequencing studies. Our results also
underscore the importance of conditional analysis for ad-
justing for the best signal of association in the GWAS
region. Lastly, our study emphasizes the need for very large
sample sizes for teasing apart independent signals (Figures
S4 and S5). For rare variants, we estimate that a sample
size of at least 3,300 RA cases and 3,300 controls would be
required for reaching a significant threshold of 2.5 3 106
(which corresponds to p ¼ 0.05 corrected for 20,000 inde-
pendent tests or genes) given the effect size observed for
IL2RA, whereas >5,500 RA cases and 5,500 controls would
be required for reaching p¼ 2.53 106 at IL2RB (Figure S4).
Our findings are consistent with the published literature on
genetic-burden tests for rare variants; no candidate-gene
study reported to date has reported anoverwhelming signal
of statistical significance.35
There are important limitations of our study. First, we
use pooled sequencing data to estimate allele frequency
in our tests of rare variants. Our sensitivity and specificity
analysis (Table S2 and Figure S1) suggest that this strategy
was effective at discovering rare variants in that it had little
evidence of false-positive findings due to technical arti-
facts. Second, we did not attempt to validate the rare vari-
ants identified in IL2RA and IL2RB by alternative methods
(like Sanger sequencing) but only used an indirect strategy
to assess the sensitivity and specificity of our sequencing
results by using GWAS data from 250 samples that were
included in our targeted sequencing. The results of this
analysis, together with the very high coverage in our
sequencing study and the stringent filters applied in
variant calling, support the quality of our sequencing
results. Third and finally, we used common variants to
match cases and controls in our pooled sequencing study.
It is possible that common variants do not adequately
capture the underlying population structure of rare vari-
ants,56 which might have biased the association statistics
in our genetic burden tests.
In conclusion, our study provides evidence of indepen-
dent RA risk alleles driven by variants in the protein-The Amcoding sequence of genes discovered by GWASs. These
alleles are rare, of low frequency, and common in the
general population, and each contributes a small effect to
disease risk. Our findings suggest that integrating sequence
data with large-scale genotyping will serve as an effective
strategy for discovering RA risk alleles in the future.Supplemental Data
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